Drug Pharmacologic class Indication More information Dermatological Disorders Rapamycin anhydrous gel, 3.9% (Palvella Therapeutics) Mechanistic/mammalian target of rapamycin pathway inhibitor ...

This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval ...

The Association of Rheumatology Professionals (ARP) has developed programming highlighting the perspectives of ...

The bispecific EGFR- and MET-directed subcutaneous coformulation produced a 42% objective response rate in the phase 1b/2 OrigAMI-4 trial for patients with pretreated recurrent or metastatic HNSCC.

This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval ...

A celebrity's recent multiple sclerosis misdiagnosis highlights the complexities of medical liability and the error in judgment defense.

Ursodeoxycholic acid recommended as first-line therapy and to prevent recurrence after liver transplant for PBC.

HealthDay News — A simple vaginal swab may one day help women with abnormal bleeding learn whether they have endometrial cancer without first going through a painful biopsy.

HealthDay News — Utah has become the first state to let an artificial intelligence (AI) program prescribe medication without a doctor writing the prescription, starting with acne treatments.

Adults with moderately to severely active Crohn disease can now self-administer risankizumab induction at home using an ...

The bispecific EGFR- and MET-directed subcutaneous coformulation produced a 42% objective response rate in the phase 1b/2 OrigAMI-4 trial for patients with pretreated recurrent or metastatic HNSCC.

The Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for ifezuntirgene inilparvovec ...